MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
Suggest Documents
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Does natalizumab therapy benefit patients with multiple sclerosis?
Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis.
Erratum: Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis.
Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis.
Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis--reply.
Natalizumab: risk stratification of individual patients with multiple sclerosis.
Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.
Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.
[Natalizumab treatment in multiple sclerosis].
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait.
Editorial: Virus markers in multiple sclerosis.
Cognitive evolution in natalizumab-treated multiple sclerosis patients.
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.
Risk acceptance in multiple sclerosis patients on natalizumab treatment.
Natalizumab in Multiple Sclerosis: Long-Term Management.
The use of natalizumab for multiple sclerosis.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy.
To evaluate the frequency of JC polyomavirus (JCPyV) infection and anti-JCPyV antibodies in patients with multiple sclerosis under natalizumab therapy...
134KB Sizes
0 Downloads
16 Views
Download PDF
Recommend Documents
JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Does natalizumab therapy benefit patients with multiple sclerosis?
Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Eosinophilic fasciitis occurring under treatment with natalizumab for multiple sclerosis.
Erratum: Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis.
Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis.
Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis--reply.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms